drugset / Trial / NCT03042819
Study of Selinexor and Doxorubicin in Advanced Soft Tissue Sarcomas
Phase 1
Completed
25 enrolled
University Health Network, Toronto
Karyopharm Therapeutics Inc · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a phase 1b study of investigational drug selinexor in combination with doxorubicin in patients with locally advanced or metastatic soft tissue sarcoma. The purpose of this study is to determine how safe and tolerable the combination is, as well as the best dose of the study drugs in this patient population. Selinexor (also called KPT-330), works by trapping "tumor suppressor proteins" within the cell and thus causing the cancer cells to die or stop growing.
Timeline
- Start
- 2017-05-16
- Primary completion
- 2019-11-30
- Completion
- 2021-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Doxorubicin | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Selinexor | Other / unclassified | 40 mg | Oral |
| Subject | Selinexor | Other / unclassified | 60 mg | Oral |
| Subject | Selinexor | Other / unclassified | 80 mg | Oral |